Klin Farmakol Farm. 2023;37(3):112-114 | DOI: 10.36290/far.2023.020

Inclisiran - a new representative of dyslipidemia biological treatment

David Karásek
III. interní klinika - nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

Inclisiran represents a new option for the biological treatment of dyslipidemia, using to suppress the production of proprotein convertase subtilisin/kexin type 9 (thus achieving a reduction in total and LDL-cholesterol levels) by inhibiting the translation of genetic information through the targeted degradation of a specific mRNA. This is a revolutionary technology that brings the possibility of long application intervals, which increases the therapeutic adherence of patients. Thanks to its highly specific effect, it is a safe treatment that is very well tolerated. Inclisiran expands the existing spectrum of lipid-lowering treatments and allows a greater number of high-risk patients to reach LDL-cholesterol target values.

Keywords: PCSK9, inclisiran, LDL-cholesterol, cardiovascular risk.

Accepted: October 12, 2023; Published: October 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D. Inclisiran - a new representative of dyslipidemia biological treatment. Klin Farmakol Farm. 2023;37(3):112-114. doi: 10.36290/far.2023.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Karásek D. Biologická léčba dyslipidémií. Vnitr. Lek. 2021; 67:206-211. Go to original source...
    2. Squizzato A, Suter MB, Nerone M, et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern. Emerg. Med. 2017;12:1043-1053. Go to original source... Go to PubMed...
    3. Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017;376:4-7. Go to original source... Go to PubMed...
    4. Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering. J Clin. Lipidol. 2022;16:574-582. Go to original source... Go to PubMed...
    5. Migliorati JM, Jin J, Zhong XB. siRNA drug Leqvio (inclisiran) to lower cholesterol. Trends Pharmacol. Sci. 2022;43:455-456. Go to original source... Go to PubMed...
    6. Macchi C, Sirtori CR, Corsini A, et al. A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacol. Res. 2019;150:104413. Go to original source... Go to PubMed...
    7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376:1430-1440. Go to original source... Go to PubMed...
    8. Hovingh GK, Lepor NE, Kallend D, et al. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020;141:1829-1831. Go to original source... Go to PubMed...
    9. Raal FJ, Kallend D, Ray KK, et al. ORION-9 Investigators. Incli­siran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl. J Med. 2020;382:1520-1530. Go to original source... Go to PubMed...
    10. Ray KK, Wright RS, Kallend D, et al. ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382:1507-1519. Go to original source... Go to PubMed...
    11. Wright RS, Ray KK, Raal FJ, et al. ORION Phase III Investigators. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021;77:1182-1193. Go to original source... Go to PubMed...
    12. Ray KK, Raal FJ, Kallend DG, et al. ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44:129-138. Go to original source... Go to PubMed...
    13. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl. J Med. 2017;376:1713-1722. Go to original source... Go to PubMed...
    14. Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome. N Engl. J Med. 2018;379:2097-2107. Go to original source... Go to PubMed...
    15. https://clinicaltrials.gov/ct2/show/NCT03705234.
    16. https://clinicaltrials.gov/ct2/show/NCT05030428.
    17. https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_cs.pdf.
    18. Karásek D. Inclisiran - nový přístup v léčbě dyslipidemie. Farmakoter Revue. 2023;8:24-27.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.